| dexamethasone / Generic mfg. |
ACTRN12621001603808: The effect of Prednisolone vs Dexamethasone on Covid-19 in Pregnancy: an open labelled randomised control trial |
|
|
| Not yet recruiting | 3 | 192 | | | Monash Health, Monash Health | covid-19, pregnancy | | | | |
ACTRN12620000291987p: An ALLG Trial to compare the use of Selinexor, Lenalidomide and Dexamethasone with Lenalidomide alone for patients with newly diagnosed Multiple Myeloma undergoing Autologous stem cell transplant. |
|
|
| Not yet recruiting | 3 | 232 | | | Australian Leukeamia and Lymphoma Group (ALLG), Karyopharm Therapeutics, Inc | Multiple Myeloma | | | | |
NCT00049478: PS-341 in Treating Patients With Refractory or Progressive Multiple Myeloma |
|
|
| Active, not recruiting | 3 | | US | bortezomib, dexamethasone | Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI) | Multiple Myeloma and Plasma Cell Neoplasm | | | | |
NCT01093196 / 2008-008606-52: Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients |
|
|
| Active, not recruiting | 3 | 660 | Europe | Melphalan, Prednisone, Lenalidomide, Cyclophosphamide, Prednisone, Lenalidomide, Lenalidomide, dexamethasone | Fondazione EMN Italy Onlus | Multiple Myeloma | 11/12 | 11/24 | | |
| Ongoing | 3 | 148 | Europe | Triamcinolone acetonide, Methylprednisolone acetate, Levobupivacaine hydrochloride, Dexamethasone, Bupivacaine hydrochloride, Lidocaine, Suspension for injection, Solution for injection, Chirocaine, lidocaine | The Walton Centre NHS Foundation Trust, NIHR Health Technology Assessment | Chronic radicular pain secondary to a prolapsed intervertebral disc herniation, Sciatica secondary to a prolapsed disc, Body processes [G] - Bones and nerves physological processes [G11] | | | | |
2014-004948-35: A randomised blinded trial of a steroid (dexamethasone) compared to a placebo for adult patients who have suffered a chronic bleed on the surface of the brain |
|
|
| Ongoing | 3 | 750 | Europe | Dexamethasone, Capsule, Dexamethasone Tablets BP 2.0mg | Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, National Institute for Health Reseach | chronic subdural haematoma, bleed on the surface of the brain, Body processes [G] - Biological Phenomena [G16] | | | | |
CINV, ChiCTR-IPR-14005265: Comparison of the effects of Palonosetron and Dexamethasone with and without Olanzapine to prevent the nausea and vomiting induced by 3-day cisplatin based chemotherapy in cancer patients: a multi cen |
|
|
| Recruiting | 3 | 178 | | Olanzapine + Palonosetron + Dexamethsone ;Palonositron | the Fourth Affiliated Hospital of China Medical University; the Fourth Affiliated Hospital of China Medical Un, self - provided | malignant neoplasm | | | | |
2007-004270-43: International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia |
|
|
| Ongoing | 3 | 1850 | Europe | 6-Mercaptopurine, Thioguanine, Daunorubicin, Prednisolone, Prednisone, Cyclophosphamide, Etoposide phosphate, Dexamethasone, Methotrexate, Cytarabine, Etoposide, Vincristine, Ifosfamide, Fludarabin, Doxorubicin, Daunoxome, Erwinase, Oncaspar, Erwinase, Oncaspar | Universitätsklinikum Schleswig-Holstein, Campus Kiel, UNIVERSITY HOSPITAL SCHLESWIG-HOLSTEIN CAMPUS KIEL | acute lymphoblastic leukemia in children and adolescents 1 to <18 years of age | | | | |
2005-006018-16: A Randomised Phase III Trial Of Low Dose DailyDexamethasone Versus Intermittent Dexamethasone Versus Prednisolone In Hormone Refractory Prostate Cancer |
|
|
| Ongoing | 3 | 90 | Europe | Prednisolone, Dexamethasone, Prednisolone, Dexamethasone, PREDNISOLONE, DEXAMETHASONE, PREDNISOLONE, DEXAMETHASONE | Royal Marsden Hospital | Hormone refractory prostate cancer | | | | |
2008-004083-39: The combination of Lenalidomide and Dexamethasone with or without intensification by high-dose Melphalan in the treatment of multiple myeloma |
|
|
| Ongoing | 3 | 348 | Europe | Dexamethasone, Melphalan, d, Mel, Revlimid, Revlimid | GMIHO Gesellschaft für Medizinische Innovation – Hämatologie und Onkologie mbH | primary treatment of multiple myeloma patients of age 60 till 75 years | | | | |
2009-016871-32: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009) |
|
|
| Ongoing | 3 | 700 | Europe | REVLIMID (LENALIDOMODE), REVLIMID (LENALIDOMIDE), VELCADE (BORTEZOMIB), REVLIMID (LENALIDOMIDE), VELCADE (BORTEZOMIB), REVLIMID (LENALIDOMIDE), VELCADE (BORTEZOMIB) | CHU de TOULOUSE, , PHRC National/Ministère de la Santé, Celgene International SARL, Janssen Pharmaceutica NV, Amgen | Myeloma, Multiple Myeloma | | | | |
2009-013856-61: Randomisierte, offene, multizentrische Phase III Studie zum Vergleich von Lenalidomid/Dexamethason versus Lenalidomid/Dexamethason mit anschließender autologer Blutstammzelltransplantation und Lenalidomid Erhaltungstherapie für Patienten mit rezidiviertem Multiplen Myelom |
|
|
| Ongoing | 3 | 282 | Europe | autologous PBSC, CD34+ cells, Revlimid®, Revlimid® | University Hospital Heidelberg, Amgen, Celgene, Chugai, Hopp-Foundation | Multiple Myeloma (1.-3. Progression/Relapse) | | | | |
2010-020174-42: Dexamethasone for the prevention of a pain flare after palliative radiotherapy for painful bone metastases: a multicenter double-blind placebo-controlled randomized study |
|
|
| Ongoing | 3 | 411 | Europe | dexamethasone, dexamethasone, dexamethasone | ZonMw | Bone metastases | | | | |
2011-004446-17: A clinical trial to investigate metoclopramide, dexamethasone or Aloxi for the prevention of nausea and vomiting occuring more than 24 hours after chemotherapy administration: the MEDEA trial |
|
|
| Ongoing | 3 | 450 | Europe | dexamethasone, METOCLOPRAMIDE HYDROCHLORIDE-0-WATER, metoclopramide-hydrochloride, dexamethasone PCH, primperan, Primperan suppository, Aloxi, dexamethasone PCH, primperan, Primperan suppository, Aloxi | VU University Medical Center Amsterdam, VU University Medical center Amsterdam | Patients with cancer receiving moderately emetogenic non-AC-based chemotherapy | | | | |
2012-004873-14: Prevention of macular edema after cataract surgery Het voorkomen van netvlieszwelling na een staaroperatie |
|
|
| Ongoing | 3 | 246 | Europe | Bromfenac, Dexamethasone, Bevacizumab, Triamcinolone Acetonide, Yellox, Dexamethasone, Avastin, Triesence, Yellox, Dexamethasone, Avastin, Triesence | University Eye Clinic Maastricht, University Eye Clinic Maastricht UMC, ESCRS (European Society of Cataract & Refractive Surgeons), Bausch + Lomb, ESCRS (European Society of Cataract and Refractive Surgeons), Bausch & Lomb | Pseudophakic cystoid macular edema (PCME) | | | | |
| Completed | 3 | 498 | Europe, US, RoW | Daratumumab, VELCADE (Bortezomib), VELCADE, Dexamethasone | Janssen Research & Development, LLC | Multiple Myeloma | 01/16 | 01/24 | | |
|
|
|
|
|
|
|
|
|
|
|
2014-003079-40: Trial in patients with newly diagnosed myeloma to evaluate the effect of elotuzumab in induction and consolidation therapy with bortezomib/lenalidomide/dexamethasone and in lenalidomide maintenance treatment Studie für Patienten mit zuvor unbehandeltem Multiplem Myelom zur Untersuchung der Wirksamkeit von Elotuzumab im Rahmen einer Induktions- und Konsolidierungstherapie mit Bortezomib/Lenalidomid/Dexamethason sowie in der Erhaltungstherapie mit Lenalidomid |
|
|
| Ongoing | 3 | 516 | Europe | Lenalidomide, Elotuzumab, CC-5013, BMS-901608, formerly known as HuLuc63, Revlimid 5 mg, Revlimid 10 mg, Revlimid 15 mg, Revlimid 25 mg, Revlimid 5 mg, Revlimid 10 mg, Revlimid 15 mg, Revlimid 25 mg | Ruprecht-Karls-University Heidelberg, Medical Faculty represented by University Hospital Heidelberg, Celgene International Sarl, Bristol-Myers Squibb International Corporation | Newly diagnosed symptomatic multiple myeloma symptomatisches Multiples Myelom, Primärtherapie | | | | |
| Active, not recruiting | 3 | 569 | Europe, Canada, Japan, US, RoW | Daratumumab, Lenalidomide, Dexamethasone | Janssen Research & Development, LLC | Multiple Myeloma | 03/16 | 08/24 | | |
|
|
|
|
|
|
|
|
|
|
|
|
NCT01685814 / 2009-016616-21: Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance |
|
|
| Active, not recruiting | 3 | 406 | Europe | Lenalidomide, Bortezomib, autologous stem cell transplant, allogeneic stem cell transplant | Wuerzburg University Hospital, ClinAssess GmbH, Celgene Corporation | Previously Untreated Symptomatic Multiple Myeloma | 09/16 | 12/23 | | |
2015-002380-42: Research study to determine whether a combination of 3 drugs calledlenalidomide, carfilzomib and dexamethasone given to persons afterautologous stem cell (a young cell without a specific purpose from whichother cell types develop) transplant is better than lenalidomidemaintenance alone. Badanie Kliniczne prowadzone celem ustalenia czy kombinacja trzechleków o nazwie lenalidomid, carfilzomib i dexametazon podana osobom poautologicznej transplantacji komórek macierzystych (pierwotne,niewyspecjalizowane komórki nie posiadające określonego przeznaczenia,które mają zdolność do przekształcania się w wyspecjalizowane komórki)jest skuteczniejsza niż podawanie samego leku lenalidomid. |
|
|
| Ongoing | 3 | 180 | Europe | Dexamethasone, Capsule, hard, Powder for solution for infusion, Tablet, Revlimid, Kyprolis | Polish Myeloma Consortium, University of Chicago, Celgene Europe Ltd | Multiple Myeloma Szpiczak Mnogi, Cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies. Nowotwór, który powstaje z komórek plazmatycznych (produkujących przeciwciała)., Diseases [C] - Cancer [C04] | | | | |
ChiCTR-IPR-15006024: A Multicenter, Randomized, Double-Blind, Controlled Phase III Study of CPT or Placebo in Combination with Thalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 3 | 417 | | Circular Permuted TRAIL+Thalidomide+Dexamethasone ;Placebo+Thalidomide+Dexamethasone | CCMU Beijing Chaoyang Hospital; Beijing Sunbio Biotech Co., Ltd, self-financing | multiple myeloma | | | | |
MAIA, NCT02252172 / 2014-002273-11: Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 737 | Europe, Canada, US, RoW | Daratumumab IV, JNJ-54767414, Lenalidomide, Dexamethasone, Daratumumab SC | Janssen Research & Development, LLC | Multiple Myeloma | 09/18 | 09/24 | | |
|
|
|
|
|
|
|
ChiCTR-OIC-17013234: A Multicenter and open-label clinical trial of efficacy and safety of Pomalidomide plus low-dose dexamethasone in patients with relapsed / refractory multiple myeloma |
|
|
| Recruiting | 3 | 70 | | Pomalidomide plus low-dose dexamethasone | Peking University People's Hospital; Peking University People's Hospital, Company funding | Multiple myeloma | | | | |
| Completed | 3 | 202 | Europe | Dexamethasone, Rituximab, Cyclophosphamide, Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib | University of Ulm, Centre Hospitalier de Lens (Co-Sponsor) | Waldenström's Macroglobulinemia | 11/18 | 04/24 | | |
ICARIA, NCT02990338 / 2016-003097-41: Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients |
|
|
| Completed | 3 | 307 | Europe, Canada, Japan, US, RoW | Isatuximab, SAR650984, Sarclisa, Pomalidomide, POMALYST IMNOVID, Dexamethasone | Sanofi | Plasma Cell Myeloma | 11/18 | 11/23 | | |
|
|
| Not yet recruiting | 3 | 294 | Europe | Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20), JnJ-54767414, Solution for injection, Capsule, Pillules, REVLIMID 25 mg gélules, NEOFORDEX 40mg comprimés | CHRU de Lille, CHU de Lille, Janssen Pharmaceutica NV | A Phase III Study Comparing Lenalidomide and Daratumumab (R-Dara) vs Lenalidomide and Dexamethasone (Rd) in Frail Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy. Etude de phase III comparant le Lénalidomide et le Daratumumab en injection sous cutanée versus le Lénalidomide et la Dexaméthasone chez des sujets fragiles atteints de myélome multiple en traitement de première ligne et non éligibles à une chimiothérapie à forte dose., Multiple Myeloma Myélome multiple, Diseases [C] - Cancer [C04] | | | | |
2018-002068-15: A RANDOMIZED TRIAL THAT COMPARE CARFILZOMIB - LENALIDOMIDE - DEXAMETHASONE versus LENALIDOMIDE - DEXAMETHASONE IN NEWLY DIAGNOSED MYELOMA PATIENTS NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) Studio randomizzato che confronta carfilzomib – lenalidomide - desametasone con lenalidomide – desametasone in pazienti affetti da mieloma multiplo di nuova diagnosi non candidabili al trapianto autologo di cellule staminali (ASCT) |
|
|
| Not yet recruiting | 3 | 340 | Europe | CARFILZOMIB, LENALIDOMIDE, DESAMETASONE, Powder for solution for infusion, Capsule, hard, Oral drops, REVLIMID 25 MG, SOLDESAM | FO.NE.SA.Onlus, Celgene, Amgen | PATIENTS WITH NEW DIAGNOSIS MM WITH AGE ≥ 65 YEARS OR NOT ELIGIBLE TO ASCT PAZIENTI CON MM DI NUOVA DIAGNOSI CON ETÀ ≥ 65 ANNI O NON ELEGGIBILI AD ASCT, PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE ≥ 65 YEARS OR NOT ELIGIBLE TO ASCT PAZIENTI AFFETTI DA MIELOMA MULTIPLO DI NUOVA DIAGNOSI CON ETÀ ≥ 65 ANNI O NON ELEGGIBILI A TRAPIANTO, Diseases [C] - Cancer [C04] | | | | |
LEPUS, NCT03234972: A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma |
|
|
| Completed | 3 | 213 | RoW | Daratumumab, Velcade, Dexamethasone | Janssen Research & Development, LLC | Multiple Myeloma | 10/19 | 02/24 | | |
2018-004031-68: Research study to comparison the effectivenes of combination of drugs called lenalidomide, carfilzomib, dexamethasone with combination of drugs called lenalidomide, bortezomib, dexamethasone, given to patients with newly diagnosed multiple myeloma Badanie kliniczne prowadzone celem porównania skuteczności terapii kombinacją leków o nazwie lenalidomid, carfilzomib, deksametazon z kombinacją leków lenalidomid, bortezomib, deksametazon, podawanych pacjentom z nowo zdiagnozowanym szpiczakiem plazmocytowym |
|
|
| Ongoing | 3 | 150 | Europe | Dexamethasone, Bortezomib, Capsule, hard, Powder and solvent for concentrate for solution for infusion, Tablet, Powder for solution for injection, Revlimid, Kyprolis, Pabi-Dexamethason, Velcade | Polish Myeloma Consortium, University of Chicago, Celgene Switzerland Holdings Sàrl | Multiple Myeloma Szpiczak plazmocytowy, Cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies Nowotwór, który powstaje z komórek plazmatycznych (produkujących przeciwciała), Diseases [C] - Cancer [C04] | | | | |
ACTRN12616000772448: A Phase 3 trial of thalidomide-dexamethasone consolidation versus thalidomide-dexamethasone-Ixazomib consolidation for transplant eligible multiple myeloma patients undergoing a single autologous stem cell transplantation as part of front-line therapy |
|
|
| Active, not recruiting | 3 | 310 | | | Australasian Leukaemia and Lymphoma Group (ALLG), Takeda Pharmaceuticals U.S.A. Inc. | Multiple Myeloma | | | | |
| Completed | 3 | 348 | Europe | Lenalidomide, Dexamethasone, Revlimid, Lenalidomide, Dexamethasone, PBSCT | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH, ClinAssess GmbH | Multiple Myeloma | 01/20 | 01/20 | | |
| Active, not recruiting | 3 | 402 | Europe, Canada, US, RoW | Selinexor, Bortezomib, Velcade®, Dexamethasone | Karyopharm Therapeutics Inc | Multiple Myeloma | 02/20 | 09/23 | | |
|
|
|
|
|
|
|
|
|
|
|
The APOLLO Study, NCT03180736 / 2017-001618-27: Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone |
|
|
| Active, not recruiting | 3 | 304 | Europe, RoW | Daratumumab, Pomalidomide, Dexamethasone | European Myeloma Network, Janssen Research & Development, LLC | Multiple Myeloma | 07/20 | 06/22 | | |
|
2020-000111-69: PACIFICA Phase 3: A Study of Pacritinib Versus Physician’s Choice in Patients with Myelofibrosis |
|
|
| Ongoing | 3 | 348 | Europe, RoW | Pacritinib, Ruxolitinib, Hydroxyurea, methylprednisolone, Dexamethasone, Prednisone, Capsule, hard, Tablet, Soluble tablet | CTI BioPharma Corp., CTI BioPharma Corp. | Primary Myelofibrosis, Post-essential thrombocythemia myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL), Post polycythaemia vera myelofibrosis, Primary or Secondary Myelofibrosis (MF), Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Active, not recruiting | 3 | 1085 | Europe | Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD), Arm A Part 1, Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab, Arm B Part 1, Daratumumab, Arm B Part 2 | Intergroupe Francophone du Myelome, HOVON - Dutch Haemato-Oncology Association, Janssen Research & Development, LLC | Multiple Myeloma | 08/20 | 06/23 | | |
|
|
|
|
NCT04499313: Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19 |
|
|
| Recruiting | 3 | 60 | RoW | Dexamethasone, Methylprednisolone | Chattogram General Hospital, Health Science Center of Xi’an Jiaotong University | Covid19, ARDS | 11/20 | 11/20 | | |
2020-004602-59: Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly diagnosed Non Frail transplant Ineligible Multiple Myeloma elderly patients (≥ 65; < 80 years). |
|
|
| Not yet recruiting | 3 | 270 | Europe | Isatuximab, Lenalidomide, Bortezomib, Isatuximab, Lenalidomide, Bortezomib, Solution for injection, Capsule, hard, Powder for solution for infusion, Isatuximab, Lenalidomide, Bortezomib | CHU DE POITIERS, CHU de Poitiers | Multiple Myeloma, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
| Active, not recruiting | 3 | 1503 | Europe, RoW | Bortezomib, Melphalan, Prednisone (VMP), 1 or 2 cycle(s) HDM (High Dose Melphalan), 2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD) | Stichting Hemato-Oncologie voor Volwassenen Nederland, European Myeloma Network, Gruppo Italiano Malattie EMatologiche dell'Adulto, DSMM (Deutsche Studiengruppe Multiples Myelom), NMSG (Nordic Myeloma Study Group), Central European Myeloma Study Group | Multiple Myeloma | 12/20 | 04/24 | | |
2020-005883-78: Comparison of Prednisolone and Dexamethasone on D28 mortality in patients on oxygen therapy with CoViD-19 Comparaison de la Prednisolone et de la Dexaméthasone sur la mortalité à J28 chez des patients sous oxygénothérapie, atteints de la CoViD-19 |
|
|
| Not yet recruiting | 3 | 220 | Europe | Solupred, Dectancyl, Orodispersible tablet, Prednisolone, Dexamethasone | Hospital Center rené Dubos, Hospital Center René Dubos | Care of severe forms of CoViD-19 from the transitional phase and the onset of the inflammatory phase with corticosteroids Prise en charge des formes sévères de CoViD-19 depuis la phase transitionnelle et le début de la phase inflammatoire par corticoïdes, Dexamethasone Prise en charge des formes sévères de CoViD-19 depuis la phase transitionnelle et le début de la phase inflammatoire par corticoïdes, Diseases [C] - Virus Diseases [C02] | | | | |
NCT02631239: MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma |
|
|
| Active, not recruiting | 3 | 256 | RoW | Methotrexate, Etoposide, Dexamethasone, Pegaspargase, Radiotherapy | Ruijin Hospital | Extranodal NK/T-cell Lymphoma, Nasal Type | 03/21 | 07/22 | | |
2020-005681-33: High versus low-dose dexamethasone for postoperative anagesia after caesarean section: a randomised, double-blind, two-center study. Hoge versus lage dosis dexamethasone voor postoperatieve pijnbestrijding na keizersnede: een gerandomiseerde, dubbel-blinde, twee-center studie. |
|
|
| Not yet recruiting | 3 | 210 | Europe | Aacidexam, Solution for injection, Aacidexam | University Hospitals Leuven, University Hospitals Leuven | postoperative analgesia after Caesarean section, Postoperative pain treatment after Caesarean section, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] | | | | |
| Recruiting | 3 | 440 | RoW | Spironolactone + Dexamethasone, Standard-of-care SARS-CoV-2 treatment | Chita State Regional Clinical Hospital Number 1 | Coronavirus Infection, Pneumonia, Viral | 07/21 | 09/21 | | |
| Completed | 3 | 60 | RoW | Celebrex, acetaminophen, and dexamethasone, Pharmacological, Saline irrigation, aspiration of pneumoperitoneum, and low pressure penumoperitoneum, Surgical | Gangnam Severance Hospital | Laparoscopic Cholecystectomy | 07/21 | 07/21 | | |
2021-001242-35: A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Stem Cell Transplant is Not Planned as Initial Therapy |
|
|
| Ongoing | 3 | 650 | Europe, RoW | Bortezomib, Lenalidomide, Dexamethasone, Ciltacabtagene Autoleucel, JNJ-68284528, Powder for solution for injection, Capsule, hard, Tablet, Dispersion for infusion, VELCADE, Revlimid, Dexamethasone | Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development, LLC, Janssen Cilag SpA | Multiple Myeloma, Newly diagnosed multiple myeloma, Diseases [C] - Cancer [C04] | | | | |
A221602, NCT03578081: Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy |
|
|
| Completed | 3 | 690 | US, RoW | Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Placebo | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Malignant Neoplasm | 11/21 | 05/23 | | |
2020-004742-11: A randomized phase 3 study of Teclistamab in combination with daratumumab verses an Investigators choice of Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Velcade, Dexamethasone in Relapsed or Refractory Multiple Myeloma |
|
|
| Ongoing | 3 | 560 | Europe | Teclistamab, Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20), Imnovid, Dexamethasone, Velcade, JNJ-64007957, JNJ-54767414, Solution for injection, Capsule, Powder for solution for injection, Darzalex, Imnovid, Neofordex, Velcade | Janssen-Cilag International NV, Janssen Research & Development, LLC | Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04] | | | | |
NCT04890626: Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19 |
|
|
| Completed | 3 | 356 | Europe | Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA], Baricitinib + dexamethasone, Dexamethasone | Instituto de Investigación Hospital Universitario La Paz | SARS-CoV-2 Infection | 07/23 | 07/23 | | |
NCT04970719: Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus |
|
|
| Withdrawn | 3 | 382 | RoW | Baricitinib, Janus kinase inhibitors, Dexamethasone, Steroids, Remdesivir, Anti-viral | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | COVID-19 Pneumonia | 12/21 | 12/21 | | |
IKEMA, NCT03275285 / 2017-001940-37: Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients |
|
|
| Active, not recruiting | 3 | 302 | Europe, Canada, Japan, US, RoW | isatuximab SAR650984, Sarclisa, carfilzomib, Kyprolis, dexamethasone | Sanofi | Plasma Cell Myeloma | 01/22 | 11/24 | | |
|
|
|
|
2020-006054-43: Randomized controlled trial to evaluate the efficacy of per-protocol administration of Methylprednisolone compared to Dexamethasone in SARS-CoV-2 infections requiring respiratory support. Studio randomizzato controllato per valutare l’efficacia della somministrazione secondo protocollo di Metilprednisolone rispetto a Desametasone nelle infezioni da SARS-CoV-2 necessitanti supporto respiratorio. |
|
|
| Not yet recruiting | 3 | 680 | Europe | Metilprednisolone, Desametasone, [MP], [DM], Solution for infusion | Università degli Studi di Trieste, Azienda Sanitaria Universitaria Giuliano-Isontina, Università degli Studi di Trieste | Hospitalized patients with COVID-19 requiring respiratory support Pazienti ospedalizzati con COVID-19 accertato con necessità di supporto respiratorio, COVID-19 COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
ChiCTR2000033109: A multicenter, randomized controlled trial for comparing lenalidomide, bortezomib, dexamethasone (RVD) combined with decitabine regimen and simple RVD regimen in the treatment of first relapse multiple myeloma |
|
|
| Recruiting | 3 | 272 | | Lenalidomide 25mg / d oral, days 6-26; bortezomib 1.3mg / m2, subcutaneous injection, administration on days 6, 9, 13, 16; dexamethasone 20mg / d, oral, days 6, 9, 13 and 16 days of administration; Decitabine, administered on days 1-5, 5-7.5mg / m2, 33 days as a course of treatment, a total. ;Lenalidomide 25mg / d orally, day 1 ~ 21; bortezomib 1.3mg / m2, subcutaneous injection, administration on days 1, 4, 8, 11; dexamethasone 20mg / d, oral, day 1, 4, 8 and 11 days of administration; 28 days is a course of treatment, a total of 8 courses of treatment. | Henan Cancer Hospital; Henan Cancer Hospital, Self-financing | Multiple myeloma | | | | |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
NCT04912271: Granisetron Transdermal Patch for Prophylaxis of Delayed CINV |
|
|
| Not yet recruiting | 3 | 140 | NA | Granisetron transdermal patch, sancuso, Palonosetron, Aprepitant, Fosaprepitant, Dexamethasone | Fudan University | Chemotherapy-induced Nausea and Vomiting (CINV) | 06/22 | 12/23 | | |
NCT05277974: Bupivicain vs Bupivicain Plus Dexamethasone in ESP Block for Post-op Analgesia |
|
|
| Recruiting | 3 | 30 | RoW | inj bupivicain, inj bupivicain plus dexamethasone | Sheikh Zayed Medical College | Post Operative Pain | 06/22 | 07/22 | | |
NCT02215980 / 2013-004166-33: STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS |
|
|
| Active, not recruiting | 3 | 210 | Europe | Lenalidomide, Dexamethasone | Fondazione EMN Italy Onlus | Multiple Myeloma | 07/22 | 07/24 | | |
| Active, not recruiting | 3 | 245 | Europe, Canada, Japan, US, RoW | Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone | Takeda | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | 08/22 | 07/27 | | |
|
|
2021-006970-22: Clinical study in order to compare the effectiveness and safety of two different treatments in patients with newly diagnosed primary immune thrombocytopenia Estudio clínico para comparar la eficacia y seguridad de dos tratamientos diferentes en pacientes con trombocitopenia inmune primaria recién diagnosticada |
|
|
| Ongoing | 3 | 126 | Europe | Powder for injection, Tablet, Romiplostim, Dexametasona 40mg | FISEVI, Ministerio de Sanidad, Consumo y Bienestar Social | Primary immune thrombocytopenia Trombocitopenia inmune primaria, Primary immune thrombocytopenia is an autoimmune blood disease characterized by the presence of low platelet levels. La trombocitopenia inmune primaria es una enfermedad de la sangre, autoinmune, caracterizada por la presencia de niveles bajos de plaquetas., Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2021-004130-11: Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D for NDMM patients who are candidates for ASCT VRD extendido más rescate temprano vs. Isatuximab-VRD vs. Isatuximab-V-Iberdomida-D en MMND candidato a TASPE |
|
|
| Not yet recruiting | 3 | 480 | Europe | Iberdomide, ISATUXIMAB, LENALIDOMIDA, BORTEZOMIB, DEXAMETHASONE, CC-220, Capsule, soft, Concentrate for solution for infusion, Capsule, hard, Powder for solution for injection, Tablet, SARCLISA, REVLIMID, BORTEZOMIB TEVA, DEXAMETASONA TAD | FUNDACION PETHEMA, FUNDACION PETHEMA | Newly-diagnosed multiple myeloma (NDMM) patients who are candidates for Autologous Stem Cell Transplant (ASCT). Mieloma múltiple de nuevo diagnóstico (MMND) candidatos a trasplante autólogo de células madre hematopoyéticas (TASPE)., Newly-diagnosed multiple myeloma (NDMM) Mieloma múltiple de nuevo diagnóstico (MMND), Diseases [C] - Cancer [C04] | | | | |
2022-000909-28: A randomized phase 3 study of Teclistamab in combination withdaratumumab and lenalidomide versus a combination of daratumumab, lenalidomide and dexamethasone in new multiple myeloma patients who cannot undergo stem cell transplant as the first therapy. |
|
|
| Ongoing | 3 | 1030 | Europe | Teclistamab, Daratumumab, Lenalidomide Accord, JNJ-64007957, JNJ-54767414, Solution for injection, Capsule, Darzalex, Lenalidomide Accord | Janssen-Cilag International NV, Janssen Research & Development, LLC | Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04] | | | | |
DREAMM-3, NCT04162210 / 2018-004252-38: Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 325 | Europe, Canada, Japan, US, RoW | Belantamab mafodotin, Pom/dex (Pomalidomide plus low dose Dexamethasone) | GlaxoSmithKline | Multiple Myeloma | 09/22 | 06/25 | | |
|
|
2021-000202-22: A Randomized Study Comparing Talquetamab in Combination WithDaratumumab and Pomalidomide or Talquetamab in Combination WithDaratumumab Versus Daratumumab, Pomalidomide and Dexamethasone, in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy |
|
|
| Ongoing | 3 | 810 | Europe, RoW | Talquetamab, Daratumumab, IMNOVID, Dexamethasone, JNJ-64407564, JNJ-54767414, Solution for injection, Capsule, hard, Tablet, Darzalex, IMNOVID, Dexamethasone JENAPHARM, Dexamethasone | Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development, LLC | Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04] | | | | |
2021-001957-30: A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide in combination with bortezomib and dexamethasone in people who have Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment. Estudio para determinar la seguridad y eficacia de CC-92480 en combinación con bortezomib y dexametasona en comparación con pomalidamida, bortezomib y dexametasona en pacientes que tienen mieloma múltiple que no responde tras tratamiento o que reaparecido tras un tratamiento |
|
|
| Not yet recruiting | 3 | 950 | Europe | CC-92480, Bortezomib, Dexamethasone, Pomalidomide/Imnovid, [.], Capsule, hard, Solution for injection, Tablet, VELCADE, Dexamethasone Aspen, Dexamethasone-ratiopharm, Imnovid, Dexamethason-JENAPHARM®, Dexamethason-Galen | Celgene Corporation, CELGENE CORPORATION, Celgene Corporation | Relapsed or Refractory Multiple Myeloma (RRMM) Mieloma Múltiple en recaída o refractario, Relapsed or Refractory Multiple Myeloma (RRMM) Mieloma Múltiple en recaída o refractario, Diseases [C] - Cancer [C04] | | | | |
ChiCTR2000036372: The effect of 585 nm wavelength light light-emitting diodes (LED) photomodulation on the treatment of melasma: A prospective, open lable, randomized controlled trial |
|
|
| Not yet recruiting | 3 | 60 | | LED 585nm wavelenth, power density 20mW/cm2，Treatment time:1000 seconds（Total energy density: 20J/cm2） ;Kligman–Willis formula (5% hydroquinone, 0.1%tretinoin, 0.1% dexamethasone) | Huashan Hospital, Fudan University; Huashan hospital, Fudan University, “Three-year-program of promoting clinical skills and clinical innovation in municipal hospitals initiated by Shenkang Hospital Development Centre | melasma | | | | |
2021-000803-20: MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Lenalidomide + Dexamethasone in Transplant-Ineligible Participants With Newly-Diagnosed Multiple Myeloma |
|
|
| Ongoing | 3 | 646 | Europe | Elranatamab, Daratumumab, Lenalidomide 5 mg, Dexamethasone 20 mg, Lenalidomide 10 mg, Lenalidomide 15 mg, Lenalidomide 20 mg, Lenalidomide 25 mg, Dexamethasone 4 mg, PF-06863135, Solution for injection, Capsule, Tablet, DARZALEX 1800 mg solution for injection | Pfizer Inc., Pfizer, Inc. | Multiple myeloma, Hematological malignancy, Diseases [C] - Cancer [C04] | | | | |
NCT04189107: Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS |
|
|
| Completed | 3 | 18 | Europe | Dexamethasone, High-dose, Placebo, Low-dose dexamethasone | Rigshospitalet, Denmark, Candys Foundation, Region Capital Denmark, Odense University Hospital, Aarhus University Hospital | Analgesia, Surgery, Cancer of Head and Neck, Oropharyngeal Cancer, Carcinoma of Unknown Primary, Pain, Postoperative, Postoperative Pain | 11/22 | 11/22 | | |
| Active, not recruiting | 3 | 1500 | Europe | Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, Brentuximab Vedotin, Dacarbazine, Dexamethasone | University of Cologne | Classical Hodgkin Lymphoma | 12/22 | 09/25 | | |
NCT02085655: PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma |
|
|
| Recruiting | 3 | 264 | RoW | pegaspargase, Oncaspar, Gemcitabine, Gemzar, Oxaliplatin, Eloxatin, Methotrexate, Dexamethasone, Thalidomide | Huiqiang Huang, Sun Yat-sen University | Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type | 12/22 | 12/22 | | |
NCT04287660: Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients |
|
|
| Recruiting | 3 | 20 | RoW | clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells | The First Affiliated Hospital of Soochow University, Changshu Frist People's Hospital, Huai'an Second People's Hospital, Affiliated Hospital of Jiangnan University, Jiangsu Province Hospital of Traditional Chinese Medicine, Jiangyin People's Hospital, Jingjiang People's Hospital, The Third People's Hospital of Kunshan, Lianyungang Hospital Affiliated Bengbu Medical College, Suzhou Municipal Hospital, Zhangjiagang First People's Hospital, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, The First Affiliated Hospital with Nanjing Medical University, The first Affiliated Hospital of Nanjing University Medical School | Multiple Myeloma | 01/23 | 01/25 | | |
2022-000996-38: Trial in patients with newly diagnosed myeloma to assess non-inferiority of induction therapy with isatuximab/lenalidomide/ bortezomib/ dexamethasone when isatuximab is administered subcutaneously versus intravenously Studie für Patienten mit zuvor unbehandeltem Multiplen Myelom zur Untersuchung der Wirksamkeit der Induktionstherapie mit Isatuximab/Lenalidomid/ Bortezomib/ Dexamethason bei Gabe von Isatuximab unter die Haut (subkutan) gegenüber einer Gabe in die Vene (intravenös) als Vergleichsmethode |
|
|
| Ongoing | 3 | 514 | Europe | Isatuximab, SAR650984, Concentrate for solution for infusion, Solution for injection | Ruprecht-Karls-Universität Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg, Sanofi-Aventis Recherche & Developpement | Newly diagnosed symptomatic multiple myeloma Symptomatisches Multiples Myelom, Primärtherapie, Symptomatic, newly diagnosed (previously untreated) multiple myeloma Bisher unbehandeltes, symptomatisches Multiples Myelom, Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 3 | 40 | RoW | Ropivacaine 0.2% Injectable Solution, Do not have, Ropivacaine 0.2% + Dexamethasone | Instituto do Coracao | Spine Erector, Cardiac Surgery, Acute Pain, Chronic Pain | 02/23 | 04/23 | | |
| Recruiting | 3 | 126 | Europe | Dexamethasone, Dexametasona kern pharma solution for injection 4 mg/ml | Hospital Universitario Infanta Leonor, Fundación para la Investigación e Innovación Biomédica del Hospital Universitario Infanta Leonor, Kern Pharma, S.L. | COVID-19, Acute Respiratory Distress Syndrome, Pneumonia, Viral | 02/23 | 03/23 | | |
| Terminated | 3 | 205 | Europe, RoW | Plitidepsin, Dexamethasone, Remdesivir, Favipiravir | PharmaMar | COVID-19 Infection | 03/23 | 03/23 | | |
ARROW2, NCT03859427 / 2018-000665-36: A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
| Completed | 3 | 454 | Europe, Japan, US, RoW | Carfilzomib, Lenalidomide, Dexamethasone | Amgen | Relapsed or Refractory Multiple Myeloma | 03/23 | 03/23 | | |
NCT05274113: Low Dose Dexamethasone for Distal Radius Fractures |
|
|
| Enrolling by invitation | 3 | 50 | US | Dexamethasone 4mg, Ropivacaine | Rothman Institute Orthopaedics | Post Operative Pain, Distal Radius Fracture | 03/23 | 03/23 | | |
| Completed | 3 | 109 | Europe | Dexamethasone phosphate | Nantes University Hospital | Sciatica | 03/23 | 03/23 | | |
NCT05006469: Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma |
|
|
| Recruiting | 3 | 10 | RoW | Bendamustine, Liposome Adriamycin, Adriamycin, dexamethasone | Liao Aijun | Bendamustine, Multiple Myeloma | 05/23 | 05/24 | | |
NCT04610398: Perioperative Dexamethasone Reduces Postoperative Pain and Nausea After Hip Arthroscopy |
|
|
| Completed | 3 | 60 | Europe | Dexamethasone 4mg, Fortecortin Inject (Merck (Switzerland)), NaCl 0.9%, NaCL Braun (B.Braun Medical) | Balgrist University Hospital | Pain, Postoperative, Nausea, Postoperative, Opioid Use | 06/23 | 06/23 | | |
| Active, not recruiting | 3 | 462 | Europe | Lenalidomide., Carfilzomib, Bortezomib, Daratumumab, Dexamethasone, Prednisone, Melphalan | PETHEMA Foundation | Newly Diagnosed Multiple Myeloma | 07/23 | 01/31 | | |
RUMBLE, NCT04144933: Effect of Multimodal Opioid-free Anesthesia on Return of Bowel Function in Laparoscopic Colorectal Surgery |
|
|
| Recruiting | 3 | 60 | Canada | Acetaminophen, Gabapentin, Opioid-free preoperative medications, Opioid-containing preoperative medications, Lidocaine 1% Injectable Solution, Dexmedetomidine, Ketamine, Opioid-free pre-intubation medications, Dexamethasone, Ondansetron, Postoperative nausea and vomiting prophylaxis, Sevoflurane, Lidocaine 2% Injectable Solution, Ketamine, Dexmedetomidine, Magnesium Sulfate, Opioid-free maintenance medications, Lidocaine 1% Injectable Solution, Sufentanil, Opioid-containing pre-intubation medications, Sevoflurane, Sufentanil, Opioid-containing maintenance medications | University of Saskatchewan | Anesthesia, General Anesthesia, Analgesics, Opioid, Opioid Free Anesthesia, Postoperative Ileus, Colorectal Surgery, Laparoscopic Surgery, Analgesia, Dexmedetomidine, Lidocaine, Ketamine | 07/24 | 08/24 | | |
ChiCTR2000036056: Compare the outcome of dexamethasone and prednisone during remission induction for intermediate/high-risk Acute Lymphoblastic Leukemia patients：A multi-institutional randomized study |
|
|
| Not yet recruiting | 3 | 2000 | | prednisone ;Dexamethasone | Shanghai Jiaotong university school of medicine affiliated Shanghai children's medical center; Shanghai Jiaotong university school of medicine affiliated Shanghai children's medical center, Project funding | Acute Lymphoblastic Leukemia | | | | |
| Recruiting | 3 | 600 | Europe | Dexamethasone Oral, Placebo oral tablet | Hospital Son Espases | Traumatic Brain Injury, Cerebral Edema | 09/23 | 02/24 | | |
DREAMM 7, NCT04246047 / 2018-003993-29: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 571 | Europe, Canada, Japan, US, RoW | Belantamab mafodotin, Daratumumab, Bortezomib, Dexamethasone | GlaxoSmithKline | Multiple Myeloma | 10/23 | 06/26 | | |
|
|
|
|
|
|
|
NCT05988671: Intraperitoneal Dexamethasone, Dexmedetomidine, and Dexamethasone-Dexmedetomidine Combination on Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy |
|
|
| Recruiting | 3 | 120 | RoW | normal Saline, Dexamethasone, Dexmedetomidine, Combination of dexamethasone + dexmedetomidine | Al-Azhar University, Benha University | Laparoscopic Cholecystectomy, Postoperative Nausea and Vomiting | 03/24 | 03/24 | | |
| Recruiting | 3 | 70000 | Europe, RoW | Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine, Azithromycin, Convalescent plasma, Tocilizumab, Immunoglobulin, Synthetic neutralising antibodies, REGEN-COV, casirivimab and imdevimab, Aspirin, Colchicine, Baricitinib, Anakinra, Dimethyl fumarate, High Dose Corticosteroid, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid, nirmatrelvir/ritonavir, Baloxavir Marboxil, Xofluza, Oseltamivir, Tamiflu, Low-dose corticosteroids: Dexamethasone | University of Oxford, UK Research and Innovation, National Institute for Health Research, United Kingdom, Wellcome, Bill and Melinda Gates Foundation, Department for International Development, United Kingdom, Health Data Research UK, Medical Research Council Population Health Research Unit, NIHR Clinical Trials Unit Support Funding, NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Flu Lab | Severe Acute Respiratory Syndrome | 06/26 | 06/36 | | |
|
| Active, not recruiting | 3 | 136 | Europe | Dexamethasone, Rituximab, Mabthera | Ostfold Hospital Trust, Oslo University Hospital, St. Olavs Hospital, Helse Stavanger HF, University Hospital of North Norway, Haukeland University Hospital, Odense University Hospital, Centre Hôpital Universitaire Farhat Hached, Henri Mondor University Hospital, University Hospital, Akershus, Cairo University | Purpura, Thrombocytopenic, Idiopathic | 12/24 | 12/24 | | |
NCT04654507: Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children |
|
|
| Recruiting | 3 | 120 | RoW | Dexamethasone Oral, corticosteroids, Placebo | Hamad Medical Corporation | Urinary Tract Infections in Children, Dexamethasone, Kidney Scarring, Acute Pyelonephritis, Hypertension in Children, Chronic Renal Failure, UTI | 12/23 | 12/24 | | |
| Recruiting | 3 | 22 | Canada | Dexamethasone, Placebo Control | The Hospital for Sick Children | Obstructive Sleep Apnea | 06/24 | 06/24 | | |
| Not yet recruiting | 3 | 150 | NA | Local anesthetic injection Bupivacaine plus dexamethasone, Local anesthetic injection bupivacainde plus dexamethasone plus a colloid, Local anesthetic injection bupivacaine plus clonidine | Universidad Simón Bolívar | Pain, Postoperative, Nausea, Postoperative, Vomiting, Postoperative, Analgesia, Opioid Use | 04/24 | 05/24 | | |
| Recruiting | 3 | 80 | Europe | Erector spinae plane block, Locoregional anaesthesia, Levobupivacaine 0,25%, chirocaine, spine fusion, NaCL 0,9%, Sufentanil, sufenta, propofol, Rocuronium Bromide, sermon, sevoflurane, paracetamol, Ketorolac, morphine pca, patient controlled analgesia, Dexamethasone, aacidexam, Morphine | Dr M. B. Breebaart | Pain, Postoperative, Anaesthesia, Surgery, Nerve Block, Anesthesia, Local, Back Pain, Spinal Fusion | 12/23 | 12/23 | | |
MK-5684-004, NCT06136650: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA |
|
|
| Recruiting | 3 | 1500 | Europe, Japan, US, RoW | Opevesostat, MK-5684, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate, Zytiga, Yonsa, Prednisone acetate, Enzalutamide, Xtandi | Merck Sharp & Dohme LLC, Orion Corporation, Orion Pharma | Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms | 12/30 | 12/30 | | |
NCT05244577: Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer |
|
|
| Recruiting | 3 | 75 | RoW | Olanzapine Tablets, Olanzapine, Placebo | Shi Yanxia | Olanzapine, CINV, Testicular Cancer by AJCC V6 and V7 Stage, Cisplatin | 12/23 | 03/24 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Opevesostat, MK-5684, Abiraterone acetate, ZYTIGA, YONSA, Enzalutamide, XTANDI, Hydrocortisone, Fludrocortisone acetate, Prednisone, Dexamethasone | Merck Sharp & Dohme LLC, Orion Corporation, Orion Pharma | Prostate Cancer Metastatic | 08/28 | 08/28 | | |
NCT05711823: Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC |
|
|
| Not yet recruiting | 3 | 300 | NA | Aprepitant in combination with granisetron and dexamethasone, Granisetron and dexamethasone | Guangxi Medical University | Hepatocellular Carcinoma | 12/24 | 12/24 | | |
HELEN-009, NCT05242874: Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer |
|
|
| Completed | 3 | 442 | RoW | Fosaprepitant , Tropisetron and Olanzapine, Standard antiemetic therapy without dexamethasone, Fosaprepitant , Tropisetron, Dexamethasone and Olanzapine, Standard antiemetic therapy | Henan Cancer Hospital | Chemotherapy-induced Nausea and Vomiting | 08/23 | 08/23 | | |
MagnetisMM-32, NCT06152575: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) |
|
|
| Recruiting | 3 | 492 | Europe, Canada, Japan, US, RoW | Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib | Pfizer | Multiple Myeloma | 12/25 | 03/28 | | |
NCT04503668: Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients |
|
|
| Terminated | 3 | 62 | US | Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA), Fosaprepitant, Olanzapine, Zyprexa, Compazine | University of Michigan Rogel Cancer Center | Gynecologic Cancer | 01/24 | 03/24 | | |
OZONE-V, NCT05346731: Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents |
|
|
| Recruiting | 3 | 210 | RoW | Ondansetron, Dexamethasone, Aprepitant, Olanzapine | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Chemotherapy-induced Nausea and Vomiting | 03/24 | 08/24 | | |
NCT02686151: The Letrozole Administration During Luteal Phase |
|
|
| Not yet recruiting | 3 | 50 | RoW | Letrozole, Femara, Polygeline, polyegline, Sodium Chloride, Natrum muriaticum, dexamethasone, dexametona | The Affiliated Hospital of Inner Mongolia Medical University | Ovarian Hyperstimulation Syndrome | 03/24 | 12/24 | | |
| Active, not recruiting | 3 | 2900 | Canada | Artesunate, Imatinib, Infliximab, Dexamethasone, LSALT Peptide | Sunnybrook Health Sciences Centre, AbbVie, Apotex Inc., World Health Organization, University of British Columbia, Arch Biopartners Inc. | COVID-19 | 03/24 | 05/24 | | |
NCT05805800: Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV |
|
|
| Recruiting | 3 | 238 | RoW | 5HT3RA+Olanzapine, 5HT3RA+Olanzapine+Dexamethasone | Xingchen Peng | Chemotherapy-induced Nausea and Vomiting | 03/24 | 03/25 | | |
